Michael Albert, MD
Ophthalmology · Birmingham, ALNPI 1730165325
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $3,384 of the $5,260 with a category attached, or 64.3%. US Retina LLC accounts for 64.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $1,684 and has fallen 83.7% since, to $275 in 2025.
Across 32 payments — averaging $164.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$3K
- Alcon$2K
- Spark Therapeutics, Inc.$100
- Johnson & Johnson Surgical Vision, Inc.$41
- Eisai Inc.$16
What the payments were for
- Food & beverage$1,87736%
- Ownership interest$3,38464%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $3,384 |
| Alcon | 22 | $1,720 |
| Spark Therapeutics, Inc. | 1 | $100 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $41 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$643
- Unity$275
- NGENUITY$138
- LUXTURNA$100
How this compares
$5,260 in reported general payments places this provider in the 80th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 128 | $5,496 |
| Ketorolac Tromethamine | 167 | $4,136 |
| Bromfenac Sodium | 15 | $2,698 |
| Difluprednate | 19 | $2,042 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $1,559 |
| Brimonidine Tartrate | 61 | $1,350 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 72 | $1,062 |
| Dorzolamide Hcl | 46 | $723 |
| Latanoprost | 35 | $701 |
| Timolol Maleate | 20 | $235 |
| Diclofenac Sodium | 15 | $182 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Birmingham
- Kristin BainsBirmingham$40K
- Lindsay RhodesBirmingham$18K
- James LewisBirmingham$15K
- Marc MichelsonBirmingham$9K
- Jennifer MichelsonBirmingham$8K
- John MasonBirmingham$7K
- Walter ParkerBirmingham$6K
- Priscilla FowlerBirmingham$6K
- Mark BearmanBirmingham$5K
- Kathleen GeeBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.